Phibro Animal Stock Price, News & Analysis

Phibro Animal Health Corporation (NASDAQ: PAHC) released its inaugural Environmental, Social and Governance (ESG) Report, establishing baseline key performance metrics as of December 31, 2021. The Report aligns with the Sustainability Accounting Standards Board (SASB) and Global Reporting Initiative (GRI) frameworks, highlighting Phibro’s commitment to sustainable animal health. The company emphasizes its responsibility to provide safe, affordable protein sustainably as global demand rises. Phibro plans to regularly review and update its ESG metrics.

Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q3 results for the period ending March 31, 2022, showing net sales of $239.6 million, up 13% year-over-year. Net income rose to $17.7 million, a 45% increase. While diluted EPS increased by 47% to $0.44, adjusted net income fell 4% to $13.4 million, with adjusted diluted EPS decreasing by 3%. The company raised its 2022 net sales guidance to $930-$950 million, but maintained adjusted EBITDA at $110-$114 million, amid ongoing macroeconomic challenges.

The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 22, 2022, to shareholders of record as of the close of business on June 1, 2022. Phibro specializes in developing and supplying a range of animal health and mineral nutrition products, aimed at promoting efficient livestock production.

Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 4, 2022, after the market closes. A conference call for analysts and investors is scheduled for May 5, 2022, at 9:00 AM Eastern Time. This call will provide insights into the company's performance and future outlook. Interested participants can access the event through Phibro's investor site or by dialing the provided numbers for U.S. and international attendees.

Phibro Animal Health Corporation (NASDAQ:PAHC) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022, at 8:00 AM ET, held in Miami Beach, Florida. CFO Damian Finio will address financial analysts and investors during the event. Attendees can access the live audio presentation through the company's Investor Relations Website. A replay will also be made available afterward. Phibro develops animal health products that aid farmers and veterinarians in producing healthy food sustainably.

Phibro Animal Health Corporation (Nasdaq:PAHC) reported strong financial results for its second quarter ending December 31, 2021, highlighting net sales of $233 million, a 13% increase from the previous year. Net income rose to $17 million, up 36%, with diluted EPS increasing to $0.43, a 34% rise. The company also revised its full-year net sales guidance upward to $890-$920 million. Key revenue drivers included improved demand in Animal Health and Mineral Nutrition segments, despite challenges from rising costs and supply chain issues. Adjusted EBITDA was reported at $29 million.

The Board of Directors of Phibro Animal Health Corporation (NASDAQ: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on March 23, 2022, to stockholders of record as of March 2, 2022. Phibro is a global leader in developing animal health and mineral nutrition products, aiding farmers and veterinarians in producing affordable food sustainably.

Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022, at 12:40 PM ET. CFO Damian Finio and EVP Daniel Bendheim will present to financial analysts and investors. The session will be available live on the company's Investor Relations Website, with a replay archived afterward. Phibro focuses on providing a wide range of animal health and mineral nutrition products, supporting sustainable food production.

Phibro Animal Health Corporation (NASDAQ: PAHC) announced that the FDA will hold a public hearing on March 10, 2022, regarding its product Mecadox® (carbadox). This antibiotic has been used in the U.S. for 50 years to control bacterial diseases in swine. The FDA seeks data on the product's safety, following past concerns about carcinogenic residues. Phibro has been proactively providing research to confirm the product's safety, stating that it will defend its continued market availability. They anticipate the hearing will support the safe use of Mecadox.